In prediabetic patients with schizophrenia-spectrum disorders on clozapine or olanzapine, 16 weeks of liraglutide did not significantly change serum cytokine levels versus placebo.
In plain wordsIn prediabetic patients with schizophrenia, liraglutide did not change blood levels of inflammation markers compared with placebo.
- Peptide
- Liraglutide
- Outcome
- No significant changeSerum cytokine concentrations (10 cytokines)
- Study
n = 77
- Comparator
- Placebo
- Outcome group
- Inflammation markers · Immune and inflammation
- Studied dose
- Dose not stated · 16 weeksAs given in this study (human).
Source sentences
No significant changes in cytokine levels following treatment with liraglutide (n = 37) vs placebo (n = 40) were found.
1 context sentence(design, population, supporting numbers)
Prediabetic patients were randomized to 16 weeks of treatment with liraglutide or placebo, and cytokines were measured again at the end of the treatment.